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Abstract
Background: Previous studies suggest a positive association between history of non-melanoma skin cancer (NMSC) and risk
of subsequent cancer at other sites. The purpose of this study is to prospectively examine the risk of primary cancer
according to personal history of NMSC.
Methods and Findings: In two large US cohorts, the Health Professionals Follow-up Study (HPFS) and the Nurses’ Health
Study (NHS), we prospectively investigated this association in self-identified white men and women. In the HPFS, we
followed 46,237 men from June 1986 to June 2008 (833,496 person-years). In the NHS, we followed 107,339 women from
June 1984 to June 2008 (2,116,178 person-years). We documented 29,447 incident cancer cases other than NMSC. Cox
proportional hazard models were used to calculate relative risks (RRs) and 95% confidence intervals (CIs). A personal history
of NMSC was significantly associated with a higher risk of other primary cancers excluding melanoma in men (RR=1.11; 95%
CI 1.05–1.18), and in women (RR=1.20; 95% CI 1.15–1.25). Age-standardized absolute risk (AR) was 176 in men and 182 in
women per 100,000 person-years. For individual cancer sites, after the Bonferroni correction for multiple comparisons
(n=28), in men, a personal history of NMSC was significantly associated with an increased risk of melanoma (RR=1.99,
AR=116 per 100,000 person-years). In women, a personal history of NMSC was significantly associated with an increased
risk of breast (RR=1.19, AR=87 per 100,000 person-years), lung (RR=1.32, AR=22 per 100,000 person-years), and
melanoma (RR=2.58, AR=79 per 100,000 person-years).
Conclusion: This prospective study found a modestly increased risk of subsequent malignancies among individuals with a
history of NMSC, specifically breast and lung cancer in women and melanoma in both men and women.
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Introduction
Non-melanoma skin cancer (NMSC) is the most common
cancer in the United States. It consists mainly of basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC). Its
incidence has been rapidly increasing over the past several
decades and the incidence rate was about 6,000/100,000 in the
year 2006 [1]. NMSC has a low mortality rate of 1/100,000 [2],
but its high prevalence and the expense of related treatment make
NMSC a major public health problem and place it among the
costliest cancers in the United States [3]. Individuals with personal
history of NMSC may be at an altered risk for developing other
primary cancers [4–11]. One view is that sunlight causes NMSC
but also produces vitamin D, which in turn may reduce the risk of
other cancers [12]. Another view is that NMSC and other cancers
may share common carcinogenic exposures or molecular mech-
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immune suppression, and thus the history of NMSC may indicate
an increased risk of subsequent cancer development.
Previous studies suggest a positive association between personal
history of NMSC and risk of subsequent cancer at other sites [4–
11]. Most previous reports, however, were based on cancer
registry data without adjustment for potential confounding lifestyle
factors [4–10]. The only cohort study was limited by its sample size
and lacked adequate power to assess individual cancer sites [11].
We carried out a cohort analysis to evaluate the association
between personal history of NMSC and subsequent malignancy in
the Nurses’ Health Study (NHS) and the Health Professionals’
Follow-up Study (HPFS).
Methods
Ethics Statement
Our study was approved by the Human Research Committee at
the Brigham and Women’s Hospital with written informed
consent from all participants.
Study Population
The NHS was established in 1976, when 121,700 registered
nurses aged 30–55 y in 11 US states responded to a baseline
questionnaire regarding risk factors for cancer. Participants
completed self-administered, mailed follow-up questionnaires
biennially with updated information on their lifestyle, diet, and
medical history. The HPFS began in 1986 when 51,529 US male
health professionals, including dentists, veterinarians, pharmacists,
and optometrists aged 40–75 y, completed a baseline question-
naire on lifestyle, diet, and newly diagnosed diseases. The
information was updated biennially with follow-up questionnaires.
The follow-up rates of the participants in both cohorts exceed
90%. These studies were approved by the Human Research
Committee at Brigham and Women’s Hospital. Race was self-
identified in this study as White, Asian, African American, and
others. Only white participants were included in this study,
accounting for 95.6% of the total population in the two cohorts.
The rationale for focusing the primary hypothesis on white
participants only was that the patterns of incidence (and likely the
risk factors) for NMSC differ widely by race.
Identification of NMSC and Other Primary Cancers
We have routinely identified cases of NMSC and other primary
cancers in both cohorts (from 1984 in the NHS and from 1986 in
the HPFS). Participants reported new diagnoses biennially. With
their permission, participants’ medical records were obtained and
reviewed by physicians to confirm their self-reported diagnosis.
Medical records were not obtained for self-reported cases of BCC,
because the validity of BCC self-reports was more than 90% in
validation studies in our cohorts in early years [13,14]. The
personal history of pathologically confirmed invasive SCC and
self-reported BCC was the exposure in this analysis. The study
outcome was the occurrence of the first confirmed primary cancer
other than NMSC. All other cancer cases were documented by
medical records or death certificates, and only confirmed cases
were included in the analysis.
Assessment of Covariates
Covariates in this analysis included age (continuous variable),
body mass index (BMI) (,21, 21–23, 23–25, 25–27, 27–29, 29–
31, .31), physical activity (quintiles), smoking status (never, past
1–14 cigarettes per day, past 15+ cigarettes per day, current 1–14
cigarettes per day, current 15+ cigarettes per day), multi-vitamin
use (yes or no), menopause status and hormone replacement
therapy use in women (pre-menopause, post-menopause non-user,
post-menopause past user, and post-menopause current user), and
physical examination in the last 2 y (yes or no). We asked about
the location of residence (US states) at birth and at age of 15 and
30. The 50 states (and the District of Columbia) were divided into
three ultraviolet (UV) index groups: 5 or less (low UV index); 6
(medium UV index); and 7 or more (high UV index) [15]. We
defined participants in these three groups if they resided in the
same UV-index region at birth, age of 15 and 30.
Statistical Analysis
Follow-up began in 1984 for the NHS and 1986 for the HPFS
when the diagnosis of NMSC was first routinely collected, and
follow-up ended in 2008 for both cohorts. Participants who
reported a history of cancer (including NMSC) prior to baseline
were excluded. Participants contributed person-time from the date
of return of the baseline questionnaire (1984 in NHS and 1986 in
HPFS) until date of diagnosis of confirmed primary cancer, date of
death, or the end of follow-up (May 31, 2008), whichever came
first. For those who were lost to follow-up, we censored them at the
return date of the last questionnaire. Cox regression analysis with
time-dependent covariates was used to determine the relative risks
(RRs) and 95% CIs of second primary malignancies associated
with a previous NMSC diagnosis. We calculated age-standardized
absolute risks (ARs) of second primary malignancies associated
with a previous NMSC diagnosis. NMSC diagnosis could change
during the follow-up period. For individuals with no personal
history of cancer at baseline who went on to be diagnosed with
NMSC as a first cancer diagnosis during follow-up, the follow-up
period before the NMSC diagnosis contributed person-time to the
non-exposure group, and the follow-up period after the NMSC
diagnosis contributed person-time to the exposure group. Age was
coded as a continuous variable in all the analyses. We showed
overall cancer risk with and without melanoma. We performed
several secondary analyses. We excluded those diagnosed with
other primary cancers within the first 4 y of NMSC diagnosis to
minimize the detection bias. We examined BCC and SCC history
separately. We performed stratified analysis according to age
(#60 y, .60 y), UV-index of residence at birth, age 15, and age
30 (#5, =6, $7), smoking status (never smoker, past smoker,
current smoker), and BMI (,25, 25–30, $30). We coded these
factors as dummy variables and tested their interactions with the
history of NMSC individually. We tested multiplicative interaction
terms by the likelihood ratio test comparing the model with the
cross-product terms with the model containing just the main
effects of these factors and the history of NMSC along with the
same covariates.
We assessed the association between NMSC diagnosis and risk
of developing site-specific cancers that were diagnosed in more
than 100 patients in each cohort. For individual cancer sites, the
Cox models additionally included risk factors specific for some
cancer sites. We included additional covariates in the multivariate
models for breast, ovarian, endometrial, prostate cancers, and
melanoma. The Bonferroni correction for p-value was applied for
multiple comparisons for individual cancer sites among men and
women, calculated as 0.05/n (n=28). Statistical analyses were
conducted using SAS software (version 9, SAS Institute). All
statistical tests were two-sided.
Results
Characteristics of our study population according to a personal
history of NMSC in mid-point of the follow-up (1998) are shown
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to be older and tended to burn and have more severe sunburns.
Participants with history of NMSC diagnosis were more likely to
have red or blonde hair and to reside in high UV-index states.
Other characteristics were similar between the exposure group
and the non-exposure group.
We followed the HPFS participants from 1986 to 2008, for a
total of 833,496 person-years. During this period, 1,577 cases of
SCC, 10,422 cases of BCC, and 10,590 primary cancer cases other
than NMSC were recorded. The mean time for the development
of a primary cancer after NMSC was 116647 mo. We followed
the NHS from 1984 to 2008 (2,116,178 person-years) during
which 2,322 cases of SCC, 21,781 cases of BCC, and 18,857
primary cancer cases other than NMSC were recorded. The mean
time for the development of a primary cancer after NMSC was
156671 mo.
A personal history of NMSC was associated with a higher risk of
other primary cancers in men (RR=1.15; 95% CI 1.09–1.22,
p,0.0001) and women (RR=1.26; 95% CI 1.21–1.31, p,0.0001)
(Table 2). The association attenuated slightly when melanoma was
excluded from the outcome in the analysis, but remained
significant in men (RR=1.11; 95% CI 1.05–1.18, p=0.0007)
and in women (RR=1.20; 95% CI 1.15–1.25, p,0.0001). Age-
standardized AR was 176 in men and 182 in women per 100,000
person-years. The association remained significant after we
excluded those diagnosed with other primary cancers within the
first 4 y of NMSC diagnosis in men (RR=1.15; 95% CI 1.05–
1.25) and women (RR=1.19; 95% CI 1.11–1.28). In men, the
association was significant according to BCC diagnosis
(RR=1.17; 95% CI 1.10–1.24) but not SCC diagnosis
(RR=1.01; 95% CI 0.87–1.17). In women, the association was
significant for both BCC (RR=1.25; 95% CI 1.20–1.30) and SCC
diagnosis (RR=1.24; 95% CI 1.10–1.39). We compared people
with personal history of SCC with people with personal history of
BCC on their risk of developing subsequent cancer, and no
significant differences were found (Table S1). In addition, we have
compared SCC in situ group with invasive SCC group and the
group of SCC or BCC; the results are shown in Table S2.
Compared to those with history of invasive SCC or those with
history of SCC or BCC, individuals with history of SCC in situ
were less likely to develop subsequent cancers. Such risk reduction
was significant among women.
No substantial differences were found in the stratified analysis
according to age, UV-index, or BMI. When stratified by smoking
status, significant associations were found in never-smokers
(RR=1.19; 95% CI 1.08–1.31 in men, and RR=1.28; 95% CI
1.20–1.38 in women) and past smokers (RR=1.12; 95% CI 1.03–
1.22 in men, and RR=1.27; 95% CI 1.20–1.35 in women), but
not in current smokers (RR=1.05; 95% CI 0.75–1.46 in men, and
RR=1.10; 95% CI 0.97–1.23 in women). The p-value for
interaction was 0.046 for men and women combined.
For individual cancer sites (Table 3), a history of NMSC was
associated with an increased risk of prostate cancer in men
(RR=1.11; 95% CI 1.02–1.20, p=0.01). The age-standardized
AR was 137 per 100,000 person-years. The RR was similar for
fatal prostate cancer (RR=1.17; 95% CI 0.89–1.53). A history of
NMSC was also associated with an increased risk of melanoma in
men (RR=1.99; 95% CI 1.63–2.43, p,0.0001). The age-
standardized AR was 116 per 100,000 person-years. In women,
a history of NMSC was associated with an increased risk of breast
cancer (RR=1.19; 95% CI 1.11–1.28, p,0.0001; AR=87 per
100,000 person-years), lung cancer (RR=1.32; 95% CI 1.14–
1.52, p=0.0002; AR=22 per 100,000 person-years), leukemia
(RR=1.30; 95% CI 1.00–1.69, p=0.05; AR=7 per 100,000
person-years), kidney cancer (RR=1.48; 95% CI 1.10–1.99,
p=0.01; AR=8 per 100,000 person-years), and melanoma
(RR=2.58; 95% CI 2.34 –2.98, p,0.0001; AR=79 per
100,000 person-years). After taking into account the multiple
comparisons for individual cancers (n=28), the associations with
breast cancer, lung cancer in women, and melanoma in both men
and women remained significant. We analyzed SCC and BCC
history separately for individual cancer sites. We observed different
rates for second cancer development according to personal history
of SCC and BCC. However, no statistically significant heteroge-
Table 1. Characteristics according to personal history of non-melanoma skin cancer in 1998.
Characteristics
a Men (HPFS) Women (NHS)
No NMSC (n=33,995) NMSC (n=4,561) No NMSC (n=83,765) NMSC (n=11,068)
Age, y (SD) 63.9 (9.2) 67.3 (9.3) 63.5 (7.1) 66.4 (6.8)
BMI, kg/m
2 (SD) 26.2 (3.8) 26.0 (3.7) 26.7 (5.4) 26.1 (5.0)
Physical activity, met-h/wk (SD) 34.6 (39.8) 36.4 (38.3) 17.1 (21.3) 18.3 (21.3)
Tendency to get painful sunburn, % 21 29 13 20
Severe sunburns .5, % 35 44 7 12
Red or blonde hair, % 14 17 15 21
UV-index at birth, age 15, and age 30 $7, % 27 32 8 13
Current smoker, % 6 5 11 10
Multi-vitamin user, % 51 57 62 65
Physical examination in the last 2 y, % 84 87 92 93
Red meat, servings/day (SD) 1.2 (0.9) 1.1 (0.8) 0.8 (0.4) 0.7 (0.4)
Fruit and vegetable, servings/day (SD) 3.3 (1.6) 3.3 (1.5) 3.2 (1.4) 3.2 (1.4)
Alcohol, gram/day (SD) 11.0 (14.1) 11.8 (14.7) 4.9 (9.0) 5.6 (9.5)
aVariables were age-standardized except for age.
SD, standard deviation.
doi:10.1371/journal.pmed.1001433.t001
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any cancer site between BCC and SCC due to the limited power
(Table S3).
Discussion
To the best of our knowledge, this is the largest prospective
study on this topic. In this study, a total of 36,102 cases of NMSC
and 29,447 cases of cancers other than NMSC were documented.
Among those with a personal history of NMSC, we found a 15%
increased risk in men and a 26% increased risk in women of
developing a second primary cancer, compared with those who
had no such history. A systematic review summarizing previous
studies revealed that NMSC is associated with more than 10%
increased risk of subsequent primary cancer in registry-based
studies and nearly 50% increased risk in cohort studies [16]. Our
Table 2. Overall and stratified analysis of risks of total subsequent primary cancers according to personal history of non-melanoma
skin cancer in men and women.
Group Cases/Person-Years AR
Age-Adjusted
RR (95% CI)
a
Multivariable-Adjusted
RR (95% CI)
b
No NMSC NMSC
Men (HPFS)
Overall 9,068/756,608 1,522/76,888 286 1.17 (1.11–1.24) 1.15 (1.09–1.22)
Overall excluding melanoma 8,513/749,343 1,380/75,916 176 1.13 (1.06–1.19) 1.11 (1.05–1.18)
SCC diagnosis history 10,405/824,054 185/9,442 110 1.04 (0.89–1.20) 1.01 (0.87–1.17)
BCC diagnosis history 9,253/766,050 1,337/67,446 305 1.18 (1.12–1.26) 1.17 (1.10–1.24)
Stratified analysis
Age #60 y 1,951/380,536 164/18,175 220 1.26 (1.07–1.48) 1.24 (1.05–1.45)
Age .60 y 7,117/376,072 1,358/58,713 292 1.16 (1.09–1.23) 1.14 (1.07–1.21)
UV-index #5 1,181/91,561 204/9,081 370 1.24 (1.05–1.46) 1.23 (1.04–1.46)
UV-index=6 2,498/196,219 451/20,502 402 1.15 (1.03–1.28) 1.15 (1.03–1.28)
UV-index $7 1,232/109,597 252/12,589 362 1.23 (1.06–1.43) 1.24 (1.07–1.44)
Never-smoker
c 3,042/292,695 538/28,361 357 1.19 (1.08–1.31) 1.19 (1.08–1.31)
Past-smoker
c 4,049/292,912 707/32,944 262 1.12 (1.03–1.22) 1.12 (1.03–1.22)
Current-smoker
c 645/46,144 72/2,962 350 1.01 (0.73–1.40) 1.05 (0.75–1.46)
BMI,25 3,890/315,048 660/33,540 258 1.15 (1.06– 1.26) 1.14 (1.05–1.25)
25#BMI,30 4,152/354,538 693/34,967 321 1.22 (1.12–1.33) 1.20 (1.10–1.31)
BMI$30 1,026/87,023 169/8,381 251 1.13 (0.94–1.36) 1.11 (0.92–1.34)
Women (NHS)
Overall 16,068/1,900,258 2,789/215,920 254 1.29 (1.23–1.34) 1.26 (1.21–1.31)
Overall excluding melanoma 15,286/1,887,665 2,501/213,349 182 1.22 (1.17–1.27) 1.20 (1.15–1.25)
SCC diagnosis history 18,575/2,095,770 282/20,408 320 1.28 (1.13–1.44) 1.24 (1.10–1.39)
BCC diagnosis history 16,350/1,920,665 2,507/195,512 246 1.27 (1.22–1.33) 1.25 (1.20–1.30)
Stratified analysis
Age #60 5,435/928,744 422/49,999 165 1.31 (1.18–1.44) 1.28 (1.16–1.42)
Age .60 10,633/937,361 2,367/160,661 298 1.28 (1.22–1.34) 1.25 (1.20–1.31)
UV-index #5 2,641/318,533 376/31,218 186 1.14 (1.02–1.27) 1.14 (1.02–1.27)
UV-index=6 5,230/608,658 987/73,647 258 1.26 (1.18–1.36) 1.28 (1.19–1.37)
UV-index $7 735/86,789 188/15,431 172 1.16 (0.98–1.38) 1.17 (0.98–1.40)
Never-smoker
c 6,046/825,740 1,011/92,124 228 1.30 (1.22–1.39) 1.28 (1.20–1.38)
Past-smoker
c 6,840/742,002 1,399/100,075 258 1.28 (1.20–1.35) 1.27 (1.20–1.35)
Current-smoker
c 2,697/253,209 346/21,941 195 1.10 (0.98–1.24) 1.10 (0.97–1.23)
BMI,25 7,177/922,638 1,422/111,181 291 1.37 (1.37–1.46) 1.31 (1.23–1.39)
25#BMI,30 5,294/600,278 871/68,370 216 1.23 (1.14–1.32) 1.21 (1.12–1.30)
BMI$30 3,597/377,342 496/36,369 242 1.23 (1.12–1.36) 1.23 (1.12–1.36)
aRR adjusted for age (continuous variable).
bMultivariate RR adjusted for age (continuous variable), BMI (,21, 21–23, 23–25, 25–27, 27–29, 29–31, .31), physical activity (quintiles), smoking status (never, past 1–
14 cigarettes per day, past 15+ cigarettes per day, current 1–14 cigarettes per day, current 15+ cigarettes per day), multi-vitamin use (yes or no), UV-index of residence at
birth, age 15, and age 30 (#5, 6, $7), physical examination in the last 2 y (yes or no), and menopause status and hormone replacement therapy use in women (pre-
menopause, post-menopause non-user, post-menopause past user, and post-menopause current user).
cStatistically significant heterogeneity between groups, p=0.046.
AR, age-standardized AR per 100,000 person-years.
doi:10.1371/journal.pmed.1001433.t002
Non-melanoma Skin Cancer and Subsequent Cancer
PLOS Medicine | www.plosmedicine.org 4 April 2013 | Volume 10 | Issue 4 | e1001433Table 3. Risks of subsequent primary cancers at different sites according to personal history of non-melanoma skin cancer in men
and women.
Cancer Cases AR
Age-Adjusted
RR (95% CI)
a
Multivariable-Adjusted
RR (95% CI)
b
No NMSC NMSC
Men (HPFS) 756,608 person-years 76,888 person-years
Prostate cancer 4,256 730 137 1.17 (1.08–1.27) 1.11 (1.02–1.20)
Lung cancer 627 97 26 0.93 (0.74–1.16) 0.99 (0.79–1.24)
Colorectal cancer 889 129 17 1.10 (0.91–1.34) 1.12 (0.92–1.36)
Bladder cancer 513 88 4 1.14 (0.90–1.45) 1.11 (0.87–1.41)
Pancreatic cancer 234 37 3 1.01 (0.70–1.45) 1.06 (0.74–1.53)
Non-Hodgkin lymphoma 312 52 3 1.17 (0.85–1.59) 1.17 (0.86–1.60)
Leukemia 327 51 6 1.08 (0.80–1.48) 1.08 (0.79–1.47)
Kidney cancer 226 31 4 1.09 (0.73–1.61) 1.08 (0.73–1.61)
Melanoma 555 142 116 2.05 (1.69–2.50) 1.99 (1.63–2.43)
c
Brain tumor 124 15 2 0.90 (0.52–1.57) 0.95 (0.54–1.65)
Oral cancer 92 11 21 0.95 (0.50–1.82) 0.95 (0.49–1.85)
Multiple myeloma 123 17 1 1.07 (0.62–1.82) 1.09 (0.63–1.87)
Others 790 122 22 1.10 (0.90–1.35) 1.11 (0.91–1.36)
Women (NHS) 1,900,258 person-years 215,920 person-years
Breast cancer 5,895 928 87 1.31 (1.22–1.41) 1.19 (1.11–1.28)
c
Endometrial cancer 1,239 168 12 1.13 (0.96–1.34) 1.16 (0.98–1.37)
Ovarian cancer 609 87 5 1.17 (0.93–1.47) 1.13 (0.89–1.42)
Lung cancer 1,298 242 22 1.35 (1.17–1.55) 1.32 (1.14–1.52)
c
Colorectal cancer 1,439 208 24 1.03 (0.89–1.19) 1.03 (0.89–1.20)
Bladder cancer 355 67 6 1.29 (0.99–1.68) 1.22 (0.93–1.60)
Pancreatic cancer 254 31 23 0.89 (0.61–1.31) 0.96 (0.65–1.40)
Non-Hodgkin lymphoma 571 101 6 1.22 (0.98–1.51) 1.15 (0.92–1.43)
Leukemia 363 70 7 1.34 (1.03–1.75) 1.30 (1.00–1.69)
Kidney cancer 269 56 8 1.48 (1.10–1.99) 1.48 (1.10–1.99)
Melanoma 782 288 79 2.70 (2.34–3.11) 2.58 (2.34–2.98)
c
Brain tumor 124 16 1 1.25 (0.73–2.12) 1.23 (0.72–2.09)
Oral cancer 95 19 6 1.75 (1.06–2.91) 1.64 (0.99–2.73)
Multiple myeloma 161 18 22 0.80 (0.49–1.31) 0.78 (0.48–1.29)
Others 2,614 490 21 1.08 (0.98–1.20) 1.12 (1.02–1.24)
AR, age-standardized AR per 100,000 person-years.
aRR adjusted for age (continuous variable).
bMultivariate RR adjusted for age (continuous variable), BMI (,21, 21–23, 23–25, 25–27, 27–29, 29–31, .31), physical activity (quintiles), smoking status (never, past 1–14
cigarettes per day, past 15+ cigarettes per day, current 1–14 cigarettes per day, current 15+ cigarettes per day), multi-vitamin use (yes or no), UV-index of residence at birth,
age 15, and age 30 (#5, 6, $7), physical examination in the last 2 y (yes or no), and menopause status and hormone replacement therapy use in women (pre-menopause,
post-menopause non-user, post-menopause past user, and post-menopause current user). For breast cancer, we additionally included in the multivariate model duration of
hormone replacement therapy use (pre-menopause, dubious menopause, post menopause age ,48 and never user, post menopause age ,48 and past user, post
menopause age ,48 and current user ,5 y, post menopause age ,48 and current user $5 y, post menopause 48,age,52 and never user, post menopause age
48,age,52 and past user, post menopause age 48,age,52 and current user ,5 y, post menopause age 48,age,52 and current user $5 y, post menopause age $52
and never user, post menopause age $52 and past user, post menopause age $52 and current user ,5 y, post menopause age $52 and current user $5 y), duration of
menopause (continuous variable), alcohol consumption (0 g/d, 0.1–4.9 g/d, 5.0–14.9 g/d, 15.0+ g/d), family history of breast cancer (yes or no), history of benign breast
disease(yesorno),height(,160.02 cm,160.02–162.56 cm,162.56–167.64 cm,$167.64 cm),weightchangefromageat18(loss.4 kg,stable,gain4–10 kg,gain10–20 kg,
gain20–40 kg,gain.40 kg),parityandage atfirst birth(nulliparous,parity1–2 andageatfirst birth,25,parity1–2 and25,ageatfirst birth ,30,parity1–2 and ageatfirst
birth .30, parity 3–4 and age at first birth ,25, parity 3–4 and 25,age at first birth ,30, parity 3–4 and age at first birth .30, parity .5 and age at first birth ,25, parity .5
and 25,age at first birth,30), andage at menarche (#12 y, 13 y, $14 y). For ovarian cancer and endometrial cancer, the multivariate modeladditionally included duration
of hormone replacement therapy use, parity and age at first birth, and age at menarche, categorized as previously. For prostate cancer, the multivariate model additionally
included height (,160.02 cm, 160.02–162.56 cm, 162.56–167.64 cm, $167.64 cm), BMI at age 21 (,21, 21–23, 23–25, 25–27, 27–29, 29–31, .31), family history of prostate
cancer (yes or no), red meat consumption (continuous variable), fruit and vegetable consumption (continuous variable), and history of prostate-specific antigen testing (yes
or no, lagged by one period to avoid counting diagnostic prostate-specific antigen tests as screening; collected from 1994 onwards). For melanoma, the multivariate model
additionally included childhood reaction to sun (some redness or none, burn, painful burn or blisters), severe sunburns (none, 1–2, 3–5, 6–9, $10), moles on the left arm
(none, 1–2, 3–5, 6–9, $10),haircolor(black,darkbrown,lightbrown,blonde,red),familyhistoryofmelanoma(yesorno),sunexposuresatdifferentageintervals(continuous
variable), UV index of residence at birth, age 15, and age 30 (#5, 6, $7).
cStatistically significant after correction for multiple comparisons, p,0.0018.
doi:10.1371/journal.pmed.1001433.t003
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analysis in two large US cohorts with more than two decades of
follow-up. The unique aspects of our study included stratified
analyses by other risk factors, disentanglement of surveillance bias,
and comprehensive adjustment for potential confounders.
It was speculated that the association between NMSC and
subsequent cancer risk may be different among people living in
locations with different UV-indexes. Specifically, southern regions
have solar UV-B radiation levels that provide sufficient vitamin D
to reduce the risk of cancer incidence, and thus inverse
associations were more likely to be found. On the contrary,
studies that found positive associations were mostly conducted in
northern regions where UV-B radiation levels do not provide
sufficient vitamin D [17,18]. In our analysis stratified by UV-
index, no substantial differences were found for the associations
between NMSC and cancer risk among locations with different
UV-indexes. To the extent that some cancers have been suggested
to be reduced with higher vitamin D [19], it might be worth noting
the fact that while colorectal cancer was not increased in this
study, it was not decreased as would be expected if NMSC were a
marker for sunlight and thus vitamin D exposure.
Intensified medical surveillance of persons with a history of
NMSC is unlikely to explain the increased cancer incidence
observed in our study. In our analysis, we adjusted for physical
examination in the last 2 y, and the result changed little. After we
excluded those diagnosed with other primary cancers within the
first 4 y of NMSC diagnosis, the association remained significant.
Compared to those with history of invasive SCC or with history of
SCC or BCC, individuals with history of SCC in situ were less
likely to develop subsequent cancers. These results suggested that
the patients who carried NMSC precursors but did not develop
skin cancers might be either less genetically susceptible or have
lower exposure. In addition, for prostate cancer, the association
remained significant for fatal prostate cancer. Furthermore, several
cancers that we observed associations with are not ones that would
be detected on routine screening. Moreover, at least one study that
assessed deaths rather than cancer incidence also found increased
cancer mortality in people with history of NMSC [20].
Several studies have observed an increased risk of NMSC after
other cancers. In one study, chronic lymphocytic leukemia patients
had an increased risk of death due to NMSC (RR=17.0, 95% CI
14.4–19.8) [21]. In another study, among 14 different sites for first
primary malignancies, 11 of these sites including prostate, breast,
and leukemia were followed by an increased risk of skin cancer (for
SCC, RR of 14.1 for males and 14.6 for females) [22]. However,
while treatment of these primary cancers may predispose to
subsequent skin cancers, most of the NMSC cases are cured by
surgical excision without any systemic chemotherapy, and
radiation, and their concomitant side effects, including possible
carcinogenicity. In addition, the similarity between the age-
adjusted and multivariate-adjusted RRs demonstrated that the
observed association between NMSC and subsequent cancers is
unlikely to be explained by confounding from smoking, obesity,
vitamin use, exercise, or any of the other measured risk factors that
we controlled for.
The link between NMSC and risk of other cancers is likely to
represent an etiologic association. For melanoma especially, the
link may be due to sun exposure. For other cancers, while there
are several explanations [23–28] of the association between
NMSC and the risk of subsequent cancer, studies have found
that certain genetic markers underlying skin cancer are also
associated with other cancer types [29]. It is biologically plausible
that deficiencies of pathways responsible for protecting against
cellular transformation in multiple tissues, such as DNA repair or
immune responses, may act systemically and play a role in
cutaneous and internal carcinogenesis.
Humans have evolved several DNA repair pathways dealing
with damage [30]. The nucleotide excision repair (NER) pathway
is responsible for the repair of a wide variety of DNA damage that
leads to distortion of the DNA helix. Such bulky DNA adducts
include UV-induced photoproducts, smoking-related benzo(a)py-
rene diolepoxide (BPDE)-DNA adducts, and other DNA damage
induced by chemical carcinogens. Reduced capacity of the NER
has been shown to confer susceptibility to certain cancers in the
general population, including melanoma, BCC, SCC, SCC of
head and neck, lung cancer, breast cancer, and bladder cancer
[31–34]. Personal history of NMSC may be a marker of
susceptibility due to reduced DNA repair capacity and it may
predict the risk of subsequent cancer development.
The NER activity has been shown to be tissue-specific. For
example, relatively low NER efficiency was observed in oral tissues
[35]. Both rapidly proliferating tissues (e.g., kidney) and slowly
proliferating tissues (e.g., lung) exhibit higher demand for NER
capacity upon stimulation to proliferation [36]. The DNA repair
system consists of several distinct pathways with many subcom-
ponents, each interacting and overlapping with one another in
order to achieve genomic stability and high fidelity. Some tissues,
such as breast, lack redundant systems of DNA repair that are
present in other tissues [37,38]. Defects in DNA repair would be
expected to have greater impact in such tissues without extensive
DNA repair redundancy. In addition, a number of studies have
suggested a role of sex hormone (e.g., estrogen and androgen) in
the regulation of DNA repair activity in breast and prostate
cancers [39]. After correction for multiple comparisons for
individual types of cancers, the significant association remained
for breast cancer, lung cancer in women, and melanoma in both
men and women. Even though the positive associations are
biologically plausible, we cannot rule out the possibility of chance
findings for each individual cancer site.
In our analysis stratified by smoking status, significant associ-
ation was found among never and past smokers. Because the NER
enzymes recognize bulky DNA adducts including both UV-
induced photoproducts and smoking-related BPDE-DNA adducts,
the interaction between smoking status and history of NMSC
highlights the potential role of the NER pathway in the
development of second cancers. However, the effect of inherited
insufficient capacity of the NER indicated by history of NMSC is
only apparent among non-current smokers and for lung cancer in
women. Further mechanistic investigation is warranted.
Sub-optimal immune surveillance could be another common
susceptibility factor for both cutaneous and internal cancers.
Malignant progression is accompanied by profound immune
suppression that interferes with an effective antitumor response
and tumor elimination [40]. Impaired immunity has been
implicated as a non-site-specific determinant of cancer risk [41].
In addition, UV radiation can also cause immunosuppression. UV
exposure adversely affects the skin immune system by diminishing
antigen-presenting cell function, inducing immunosuppressive
cytokine production, and modulating contact and delayed-type
hypersensitivity reactions [42,43], all of which can reduce the
body’s surveillance for tumor cells [44,45]. UV suppresses immune
reactions locally, but can also affect the immune system in a
systemic fashion when higher UV doses are given [46,47]. UV
radiation affects immune surveillance by modulating the balance
between an effective immune response and immune tolerance of
an emerging cancer [41]. We did not observe an association
between UV-index and the risk of cancer except for skin cancer in
our study, which makes this explanation less likely for our findings.
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report without pathological confirmation. However, the partici-
pants in the two cohorts were nurses and health professionals. The
validity of their reports was expected to be high, and it has been
proven in our validation studies [13,14]. In addition, previous
studies of BCC in the NHS using the self-reported cases identified
both constitutional and sun exposure risk factors as expected, such
as lighter pigmentation, less childhood and adolescent tanning
tendency, higher tendency to sunburn, and tanning salon
attendance [48,49]. We recently confirmed the MC1R gene as
the top BCC risk locus using the NHS and HPFS samples [50].
These data together suggest that the bias due to self-report of BCC
is likely to be minimal in our study. Moreover, the potential under-
report of BCC diagnosis would be expected to bias observed
associations toward the null, and such bias would not explain the
positive associations that we found.
The strengths of our study included the prospective cohort
design and updated assessment of cancer diagnosis and other risk
factors every 2 y, more than two decades of follow-up, and a large
number of incident skin cancer cases. We had detailed data on
related covariates for stratified analyses and comprehensive
adjustment for potential confounders. All the participants were
health professionals, minimizing potential confounding by educa-
tional attainment or differential access to health care. Neverthe-
less, we cannot completely exclude residual confounding, and our
findings may not assign causality. Although the observed
significant associations in breast cancer, lung cancer in women,
and melanoma in both men and women remained significant after
correction for multiple comparisons, we cannot absolutely rule out
chance findings for individual cancer sites, and the underlying
mechanism for the associations found in specific cancer sites is not
entirely clear. In addition, the significant associations for some
individual cancers did not meet the adjusted p-value threshold
because of their limited sample size.
We cannot estimate the recurrence rate of NMSC or
subsequent cancer risk among people with multiple NMSC
because we only recorded the first report of each type of skin
cancer in both cohorts. We do not have data for non-whites in this
study, and our results cannot be generalized to non-whites owing
to the dramatic difference in skin cancer incidence among different
races. In summary, we observed a modestly increased risk of other
cancers among individuals with a history of NMSC. Because our
study was observational, these results should be interpreted
cautiously and are insufficient evidence to alter current clinical
recommendations. Nevertheless, these data support a need for
continued investigation of the potential mechanisms underlying
this relationship.
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Background. In the United Kingdom and the United States,
about one in three people develop cancer during their
lifetime and, worldwide, cancer is responsible for 13% of all
deaths. Primary cancer, which can develop anywhere in the
body, occurs when a cell begins to divide uncontrollably
because of alterations (mutations) in its genes. Additional
mutations allow the malignancy to spread around the body
(metastasize) and form secondary cancers. The mutations
that initiate cancer can be triggered by exposure to
carcinogens such as cigarette smoke (lung cancer) or the
ultraviolet (UV) radiation in sunlight (skin cancers). Other risk
factors for the development of cancer include an unhealthy
diet, physical inactivity, and alcohol use. In the United States,
the most common cancer is non-melanoma skin cancer
(NMSC). Although more than 2 million new cases of NMSC
occur each year, fewer than 1,000 people die annually in the
United States from the condition because the two types of
NMSC—basal cell carcinoma and squamous cell carcinoma—
rarely metastasize and can usually be treated by surgically
removing the tumor.
Why Was This Study Done? Some studies have suggest-
ed that people who have had NMSC have a higher risk of
developing primary cancer at other sites than people who
have not had NMSC. Such a situation could arise if exposure
to certain carcinogens initiates both NMSC and other cancers
or if NMSC shares a molecular mechanism with other cancers
such as a deficiency in the DNA repair mechanisms that
normally remove mutations. If people with a history of NMSC
are at a greater risk of developing further cancers, a specific
surveillance program for such people might help to catch
subsequent cancers early when they can be successfully
treated. In this prospective cohort study, the researchers
examine the risk of primary cancer according to personal
history of NMSC in two large US cohorts (groups)—the
Health Professionals Follow-up Study (HPFS) and the Nurses’
Health Study (NHS). The HPFS, which enrolled 51,529 male
health professionals in 1986, and the NHS, which enrolled
121,700 female nurses in 1976, were both designed to
investigate associations between nutritional factors and the
incidence of serious illnesses. Study participants completed a
baseline questionnaire about their lifestyle, diet and medical
history. This information is updated biennially through
follow-up questionnaires.
What Did the Researchers Do and Find? The researchers
identified 36,102 new cases of NMSC and 29,447 new cases
of other primary cancers from 1984 in white NHS participants
and from 1986 in white HPFS participants through 2008.
They then used statistical models to investigate whether a
personal history of NMSC was associated with a higher risk of
subsequent primary cancers after accounting for other
factors (confounders) that might affect cancer risk. A history
of NMSC was significantly associated with an 11% higher risk
of other primary cancers excluding melanoma (another type
of skin cancer that, like NMSC, is linked to overexposure to
UV light) in men and a 20% higher risk of other primary
cancers excluding melanoma in women; a significant
association is one that is unlikely to have happened by
chance. The absolute risk of a primary cancer among men
and women with a history of NMSC was 176 and 182 per
100,000 person-years, respectively. For individual cancer
sites, after correction for multiple comparisons (when several
conditions are compared in groups of people, statistically
significant differences between the groups can occur by
chance), a history of NMSC was significantly associated with
an increased risk of breast and lung cancer in women and of
melanoma in men and women.
What Do These Findings Mean? These findings suggest
that there is a modestly increased risk of subsequent
malignancies among white individuals with a history of
NMSC. Although the researchers adjusted for many con-
founding lifestyle factors, the observed association between
NMSC and subsequent primary cancers may nevertheless be
the result of residual confounding, so it is still difficult to be
sure that there is a real biological association (due to, for
example, a deficiency in DNA repair) between NMSC and
subsequent primary cancers. Because of this and other study
limitations, the findings reported here should be interpreted
cautiously and do not suggest that individuals who have had
NMSC should undergo increased cancer surveillance. These
findings do, however, support the need for continued
investigation of the apparent relationship between NMSC
and subsequent cancers.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001433.
N The US National Cancer Institute provides information on
all aspects of cancer and has detailed information about
non-melanoma skin cancer for patients and professionals
(in English and Spanish)
N The non-profit organization American Cancer Society
provides information on cancer and how it develops and
specific information on skin cancer(in severallanguages); its
website includes personal stories about cancer
N The UK National Health Service Choices website includes
an introduction to cancer and a page on non-melanoma
skin cancer
N The non-profit organization Cancer Research UK provides
basic information about cancer and detailed information
on non-melanoma skin cancer
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